IBDEI1MC ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27085,0)
 ;;=L40.2^^132^1309^11
 ;;^UTILITY(U,$J,358.3,27085,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27085,1,3,0)
 ;;=3^Acrodermatitis Continua
 ;;^UTILITY(U,$J,358.3,27085,1,4,0)
 ;;=4^L40.2
 ;;^UTILITY(U,$J,358.3,27085,2)
 ;;=^5009162
 ;;^UTILITY(U,$J,358.3,27086,0)
 ;;=L40.3^^132^1309^255
 ;;^UTILITY(U,$J,358.3,27086,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27086,1,3,0)
 ;;=3^Pustulosis Palmaris et Plantaris
 ;;^UTILITY(U,$J,358.3,27086,1,4,0)
 ;;=4^L40.3
 ;;^UTILITY(U,$J,358.3,27086,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,27087,0)
 ;;=L40.4^^132^1309^157
 ;;^UTILITY(U,$J,358.3,27087,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27087,1,3,0)
 ;;=3^Guttate Psoriasis
 ;;^UTILITY(U,$J,358.3,27087,1,4,0)
 ;;=4^L40.4
 ;;^UTILITY(U,$J,358.3,27087,2)
 ;;=^5009164
 ;;^UTILITY(U,$J,358.3,27088,0)
 ;;=L40.8^^132^1309^252
 ;;^UTILITY(U,$J,358.3,27088,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27088,1,3,0)
 ;;=3^Psoriasis NEC
 ;;^UTILITY(U,$J,358.3,27088,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,27088,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,27089,0)
 ;;=L40.9^^132^1309^254
 ;;^UTILITY(U,$J,358.3,27089,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27089,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,27089,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,27089,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,27090,0)
 ;;=L50.9^^132^1309^286
 ;;^UTILITY(U,$J,358.3,27090,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27090,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,27090,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,27090,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,27091,0)
 ;;=L53.8^^132^1309^147
 ;;^UTILITY(U,$J,358.3,27091,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27091,1,3,0)
 ;;=3^Erythematous Conditions NEC
 ;;^UTILITY(U,$J,358.3,27091,1,4,0)
 ;;=4^L53.8
 ;;^UTILITY(U,$J,358.3,27091,2)
 ;;=^88044
 ;;^UTILITY(U,$J,358.3,27092,0)
 ;;=L53.9^^132^1309^146
 ;;^UTILITY(U,$J,358.3,27092,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27092,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,27092,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,27092,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,27093,0)
 ;;=L54.^^132^1309^145
 ;;^UTILITY(U,$J,358.3,27093,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27093,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,27093,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,27093,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,27094,0)
 ;;=L56.0^^132^1309^139
 ;;^UTILITY(U,$J,358.3,27094,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27094,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,27094,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,27094,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,27095,0)
 ;;=L56.1^^132^1309^138
 ;;^UTILITY(U,$J,358.3,27095,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27095,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,27095,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,27095,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,27096,0)
 ;;=L56.2^^132^1309^236
 ;;^UTILITY(U,$J,358.3,27096,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27096,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,27096,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,27096,2)
 ;;=^5009216
 ;;^UTILITY(U,$J,358.3,27097,0)
 ;;=L56.3^^132^1309^268
 ;;^UTILITY(U,$J,358.3,27097,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27097,1,3,0)
 ;;=3^Solar Urticaria
 ;;^UTILITY(U,$J,358.3,27097,1,4,0)
 ;;=4^L56.3
 ;;^UTILITY(U,$J,358.3,27097,2)
 ;;=^5009217
 ;;^UTILITY(U,$J,358.3,27098,0)
 ;;=L57.0^^132^1309^12
 ;;^UTILITY(U,$J,358.3,27098,1,0)
 ;;=^358.31IA^4^2
